Back to top
more

Sangamo Therapeutics (SGMO)

(Real Time Quote from BATS)

$0.25 USD

0.25
5,523,525

0.00 (-1.85%)

Updated Apr 9, 2026 09:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Has Sangamo Therapeutics (SGMO) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is Sangamo Therapeutics, Inc. (SGMO) Outperforming Other Medical Stocks This Year?

    Zacks Equity Research

    Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

    by Zacks Equity Research

    Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

      Zacks Equity Research

      Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio

      by Zacks Equity Research

      Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio

        Kevin Cook headshot

        Recession is Coming! Not

        by Kevin Cook

        Even if Dalio is only half right, we can bank on the "melt up" and monitor the data like an interest rate hawk

          Zacks Equity Research

          Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 14.4% in Session

          by Zacks Equity Research

          Sangamo Therapeutics (SGMO) shares rose more than 14% in the last trading session, amid huge volumes.

            Zacks Equity Research

            Pfizer (PFE) Collaborates With Sangamo for Gene Therapy

            by Zacks Equity Research

            Pfizer entered into collaboration agreements with Sangamo Therapeutics and private biotech, Arvinas.

              Arpita Dutt headshot

              Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer

              by Arpita Dutt

              Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.

                Zacks Equity Research

                The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical

                by Zacks Equity Research

                The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical

                  Zacks Equity Research

                  4 Biotech Stocks Ready to Crush the Market in 2018

                  by Zacks Equity Research

                  The biotech sector has performed well in 2017 and we expect the momentum to continue in 2018 driven by new drug approvals. Here, we list stocks which might be worth adding to your biotech portfolio for 2018.

                    Benjamin Rains headshot

                    3 Buy-Ranked Biotech Stocks That Soared in 2017

                    by Benjamin Rains

                    The S&P 500 is up almost 20% in 2017, with the likes of technology giants Nvidia (NVDA) and Amazon (AMZN) helping lift the index to new heights.